COMPLIANT INTERACTIONS WITH SPECIALTY PHARMACIES

20th Annual Pharmaceutical and Medical Device Compliance Congress

November 7, 2019

THE PANEL



Timothy Ayers, JD, MPH
Life Science Compliance Consulting, LLC Former VP, Chief
Compliance Officer, Horizon Pharma plc., Oklahoma City, OK



Mark A. DeWyngaert, PhD

Managing Director, Deloitte Advisory, Deloitte & Touche LLP, Stamford, CT




Richard Liner, JD, MPH
Senior Counsel, Compliance and Investigations, Bayer Healthcare, Whippany, NJ



Sarah diFrancesca, JD
Partner, Health Care and Life Sciences Regulatory Practice, Cooley LLP, New York
Moderator

SPECIALTY PHARMACY BUSINESS MODEL



INDUSTRY ENFORCEMENT EXAMPLE

- Novartis \$390M civil settlement to resolve FCA allegations that it paid kickbacks to specialty pharmacies
 - Incentivized and pressured the pharmacies to emphasize Exjade's benefits to patients while understating the drug's serious side effects
 - Rebates used to induce the pharmacies to recommend to doctors that they switch patients to Myfortic from competitor drugs
- 3 parallel settlements:
 - US Bioservices: \$13.4M
 - Accredo Health Group: \$60M
 - BioScrip: \$15M

"Novartis turned pharmacies that should have been disinterested healthcare providers into a biased salesforce for the drug-maker.

Drug-makers and their relationships with healthcare providers — whether they are doctors, pharmacists, or nurses — must comply with the Anti-Kickback Statute."

- Manhattan U.S. Attorney Preet Bharara

EVOLVING ROLE OF SPECIALTY PHARMACIES

- Defining "specialty pharmacy"
- Evolving list of services provided by specialty pharmacies
- Exclusive vs. non-exclusive specialty pharmacies
- Specialty pharmacy interactions with HUB
- Specialty pharmacy interactions with patient support programs / charitable foundations
- Specialty pharmacy interactions with manufacturer sales team

OTHER KEY COMPLIANCE RISKS AND RISK MITIGATION

- Privacy / HIPAA
- Contract negotiations
- Performance metrics / ROI
- Auditing and monitoring